Otsuka Pharmaceutical Co. Ltd.
www.otsuka.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Otsuka Pharmaceutical Co. Ltd.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.
Otsuka Progresses Digital Push With US Approval Of MDD App
Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.
Ionis 12-Month FCS Data Position Olezarsen For Near-Term Filing
Showing its antisense drug can reduce triglycerides and risk of acute pancreatitis in familial chylomicronemia syndrome, Ionis plans to file olezarsen for approval soon, hoping for accelerated approval.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
In Vitro Diagnostics
- Chemistry, Immunoassay
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice